Anti-Caveolin-3 antibody [EPR11082] (ab173575)


  • Product name
    Anti-Caveolin-3 antibody [EPR11082]
    See all Caveolin-3 primary antibodies
  • Description
    Rabbit monoclonal [EPR11082] to Caveolin-3
  • Host species
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human Caveolin-3 aa 1-100 (N terminal) (Cysteine residue). The exact sequence is proprietary.
    Database link: P56539

  • Positive control
    • Human skeletal muscle and fetal heart lysates
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    A trial size is available to purchase for this antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents



Our Abpromise guarantee covers the use of ab173575 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Predicted molecular weight: 17 kDa.
  • Application notes
    Is unsuitable for ICC/IF,IHC-P or IP.
  • Target

    • Function
      May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. May also regulate voltage-gated potassium channels. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress.
    • Tissue specificity
      Expressed predominantly in muscle.
    • Involvement in disease
      Defects in CAV3 are the cause of limb-girdle muscular dystrophy type 1C (LGMD1C) [MIM:607801]. LGMD1C is a myopathy characterized by calf hypertrophy and mild to moderate proximal muscle weakness. LGMD1C inheritance can be autosomal dominant or recessive.
      Defects in CAV3 are a cause of hyperCKmia (HYPCK) [MIM:123320]. It is a disease characterized by persistent elevated levels of serum creatine kinase without muscle weakness.
      Defects in CAV3 are a cause of rippling muscle disease (RMD) [MIM:606072]. RMD is a rare disorder characterized by mechanically triggered contractions of skeletal muscle. In RMD, mechanical stimulation leads to electrically silent muscle contractions that spread to neighboring fibers that cause visible ripples to move over the muscle.
      Defects in CAV3 are a cause of cardiomyopathy familial hypertrophic (CMH) [MIM:192600]; also designated FHC or HCM. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
      Defects in CAV3 are the cause of long QT syndrome type 9 (LQT9) [MIM:611818]. Long QT syndromes are heart disorders characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to excercise or emotional stress. They can present with a sentinel event of sudden cardiac death in infancy.
      Defects in CAV3 can be a cause of sudden infant death syndrome (SIDS) [MIM:272120]. SIDS is the sudden death of an infant younger than 1 year that remains unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of clinical history. Pathophysiologic mechanisms for SIDS may include respiratory dysfunction, cardiac dysrhythmias, cardiorespiratory instability, and inborn errors of metabolism, but definitive pathogenic mechanisms precipitating an infant sudden death remain elusive. Long QT syndromes-associated mutations can be responsible for some SIDS cases.
    • Sequence similarities
      Belongs to the caveolin family.
    • Cellular localization
      Golgi apparatus membrane. Cell membrane. Membrane > caveola. Potential hairpin-like structure in the membrane. Membrane protein of caveolae.
    • Information by UniProt
    • Database links
    • Alternative names
      • CAV3 antibody
      • CAV3_HUMAN antibody
      • Caveolin 3 antibody
      • Caveolin-3 antibody
      • LGMD1C antibody
      • LQT9 antibody
      • M-caveolin antibody
      • MGC126100 antibody
      • MGC126101 antibody
      • MGC126129 antibody
      • OTTHUMP00000115603 antibody
      • OTTHUMP00000207105 antibody
      • VIP 21 antibody
      • VIP21 antibody
      see all


    • All lanes : Anti-Caveolin-3 antibody [EPR11082] (ab173575) at 1/1000 dilution

      Lane 1 : Human Skeletal Muscle Lysate
      Lane 2 : Fetal Heart Lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 17 kDa


    This product has been referenced in:
    • Gutierrez-Pajares JL  et al. Caveolin-3 Promotes a Vascular Smooth Muscle Contractile Phenotype. Front Cardiovasc Med 2:27 (2015). Read more (PubMed: 26664898) »

    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab173575.
    Please use the links above to contact us or submit feedback about this product.


    Sign up